PE firm buys GSK spinoff Neomed-Labs as it looks to ‘flip the next page’ of its story

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/anyaivanova)
(Image: Getty/anyaivanova)

Related tags Gsk Private equity Ampersand Capital PE Lab research Laboratory Immunology

Neomed-Labs is aiming to double in size and become a global leader in clinical immunology lab services with an investment from Ampersand Capital.

The middle market private equity (PE) firm Ampersand Capital acquired the clinical immunology laboratory services provider Neomed-Labs from its not-for-profit founder and parent, the Neomed Institute.

The investment will be used to fuel both organic and inorganic growth initiatives, explained Mounia Azzi, chief business officer of Neomed-Labs.

According to the company – which was formed in April 2015 as a spinoff from GSK’s Clinical Laboratory Services unit – in addition to expanding its presence in Quebec, it also will pursue expansion into adjacent markets and geographies.

Azzi said the rationale behind the deal is “to flip the next page of our story after three years as a subsidiary of a non-for-profit organization whose mandate is clearly not to be a shareholder in health care service provider companies.”

“Partnering with a health care mid-market reference private equity group will enable us to fund organic and inorganic initiatives required to become the obvious global leader in clinical immunology lab services,”​ she told us.

As per next steps in the company’s evolution, Azzi said the it is “quite realistic”​ that it could double its size organically in 24 months based on the current backlog and client base.

Neomed-Labs also will look to add services to its portfolio, “so that we can tackle other clinical immunology opportunities than infectious vaccines, currently our core business,”​ she explained.

Ampersand’s current portfolio of includes several service providers, such as Brammer Bio​, Avista Pharma​, bioventus, MedPharm, KeyBiologics, among others.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Related suppliers